Background: The mitochondrial enzyme amyloid beta-binding alcohol dehydrogenase (ABAD) also known as 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) has been connected with the pathogenesis of Alzheimer's disease (AD). ABAD/ 17β-HSD10 is a binding site for the amyloid-beta peptide (Aβ) inside the mitochondrial matrix where it exacerbates Aβ toxicity. Interaction between these two proteins triggers a series of events leading to mitochondrial dysfunction as seen in AD. Methods: As ABAD's enzymatic activity is required for mediating Aβ toxicity, its inhibition presents a promising strategy for AD treatment. In this study, a series of new benzothiazolylurea analogues have been prepared and evaluated in vitro for their potency to inhibit ABAD/ 17β-HSD10 enzymatic activity. The most potent compounds have also been tested for their cytotoxic properties and their ability to permeate through blood-brain barrier has been predicted. To explain the structure-activity relationship QSAR and pharmacophore studies have been performed. Results and Conclusions: Compound 12 was identified being the most promising hit compound with good inhibitory activity (IC50 = 3.06 ± 0.40µM) and acceptable cytotoxicity profile comparable to the parent compound of frentizole.
Introduction
Alzheimer's disease (AD) is the most common cause of senile dementia. About 20 million people worldwide suffer from this devastating illness [1] . AD is characterized by progressive decline of cognitive functions and memory. Despite intensive research, the pathogenic mechanisms of AD are still not fully understood and consequently no effective treatment has been yet developed.
The main pathological hallmarks of AD represents extracellular amyloid-beta peptide (Aβ) deposits also termed senile plaques, intracellular deposits of phosphorylated τ-protein, termed neurofibrillary tangles, and loss of neurons [2, 3] . Although the aetiology of AD is still not known, buildup of Aβ is considered to play an important part in disease progression. The original amyloid cascade hypothesis suggested that extracellular plaques are the main toxic form of Aβ. However, recent data indicates that soluble intracellular oligomers are responsible for most of Aβ toxicity [4] [5] [6] [7] [8] .
Inside the cell, Aβ interacts with a number of proteins including amyloid-binding alcohol dehydrogenase (ABAD), also referred as 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) [9] , an enzyme located within mitochondrial matrix capable to catalyse oxidation of alcohols and reduction of aldehydes and ketones.
As cells expressing catalytically inactive mutants of ABAD/ 17β-HSD10 show decreased sensitivity to Aβ, it has been suggested that the ABAD/ 17β-HSD10 enzymatic activity is required for mediating Aβ toxicity [10] . Therefore, inhibition of ABAD/ 17β-HSD10 is a possible strategy for AD treatment, which has already been indicated with the use of a small molecule ABAD/ 17β-HSD10 inhibitor AG18051. AG18051 is an irreversible ABAD/ 17β-HSD10 inhibitor reported to create a covalent bond with the cofactor NAD + within the enzyme's active site, and was shown subsequently to ameliorate Aβ toxicity in cell based studies [11, 12] .
Previously, frentizole and its analogues were found to be inhibitors of the ABAD-Aβ interaction, which presents another approach of targeting ABAD/ 17β-HSD10 for AD treatment [13, 14] . Assuming that this effect was due to binding of these compounds to ABAD/ 17β-HSD10, some frentizole analogues were also tested as ABAD/ 17β-HSD10 inhibitors, which led to the discovery of a novel class of ABAD/ 17β-HSD10 inhibitors [15] . Similarly to AG18051, this new class of ABAD/ 17β-HSD10 inhibitors have cytoprotective effects in cells treated with Aβ [12, 15] .
Additionally to AD treatment ABAD/ 17β-HSD10 inhibition could be also employed in treatment of certain types of prostatic cancer, where overexpression of ABAD/ 17β-HSD10 takes place allowing the cancer cells to generate 5α-dihydrotestosterone in the absence of testosterone [16, 17] .
However, currently known ABAD/ 17β-HSD10 inhibitors (Fig. 1 ) suffer from some considerable drawbacks making them poor lead drug-like candidates. Compound AG18051 creates a covalent bond with NAD + cofactor within the enzyme's active site and with such mechanism of action it is likely to affect also other NAD+ dependant enzymes [11] . Compound RM-532-46 could suffer from specificity 3 issues as well, because it comprises a steroidal structural scaffold, which could be recognized by other steroid-binding sites [18] . Recently identified phosphonate-benzothiazole inhibitors showed rather poor activity with best compound having IC50 value of 52.7 μM [15] . Hence there is a need for developing novel ABAD/ 17β-HSD10 inhibitors with improved properties. In this study we have designed, synthesized and evaluated in vitro a series of novel 6benzothiazolyl ureas, thioureas and guanidines. The most promising compounds have been further assessed for their cytotoxic properties and ability to cross the blood-brain barrier (BBB).
MATERIALS AND METHODS

General chemistry
Solvents and reagents were purchased from Fluka and Sigma-Aldrich (Czech Republic) and used without further purification. Reactions were monitored by TLC performed on aluminium sheets precoated with silica gel 60 F254 (Merck, Czech Republic) using mobile phase CHCl3/MeOH 50:1 For HRMS determination, a Dionex UltiMate 3000 analytical LC-MS system coupled with a Q Exactive Plus hybrid quadrupole-orbitrap spectrometer (both produced by ThermoFisher Scientific, Bremen, Germany) was used. The LC-MS system consisted of a binary pump HPG-3400RS connected to a vacuum degasser, a heated column compartment TCC-3000, an autosampler WTS-3000 equipped with a 25 μL loop and a VWD-3000 ultraviolet detector. A Waters Atlantis dC18 100Å (2.1 x 100mm/3µm) column was used as the stationary phase. The analytical column was protected against mechanical particles by an in-line filter (Vici Jour) with a frit of 0.5µm pores. Water (MFA) and acetonitrile (MFB) used in the analyses were acidified with 0.1% (v/v) of formic acid. Ions for mass spectrometry (MS) were generated by heated electro-spray ionization source (HESI) working in positive mode, with the following settings: sheath gas flow rate 40, aux gas flow rate 10, sweep gas flow rate 2, spray voltage 3.2 kV, capillary temperature 350°C, aux gas temperature 300°C, S-lens RF level 50, microscans 1, maximal injection time 35ms, resolution 140 000. The full-scan MS analyses monitored ions within m/z range 100 -1500. The studied compounds were dissolved in methanol and 1µL of the solution was injected into the LC-MS system. For elution, following ramp-gradient program was used: 0 -1 min: 10% MFB, 1 -4 min: 10% -100% MFB, 4 -5 min: 100% MFB, 5 -7.5 min: 10% MFB. The flow-rate in the gradient elution was set to 0.4 mL/min. To increase the accuracy of HRMS, internal lock-mass calibration was employed using polysiloxane traces of m/z = 445.12003 ([M+H] + , [C2H6SiO]6) present in the mobile phases. The chromatograms and mass spectra were processed in Chromeleon 6.80 and Xcalibur 3.0.63 software, respectively.
Elemental analysis (EA) was measured at Perkin-Elmer CHN Analyser 2400 Series II apparatus.
Physical-chemical properties calculation and measurement
Physical-chemical properties of prepared compounds in the unionized form were calculated in ACDLabs PhysChem Suite 2014 [20] .
The method of measurement and calculation of ElogP was adapted from Technical guide OECD No. 117 [21] . Based on this method, the ElogD was determined accordingly [22] . All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA). Seven standard stock solutions were prepared by dissolving nitrobenzene (ReagentPlus, 99%), chlorobenzene (puriss. p.a., ACS reagent, ≥99.5%), thymol A test for compound active site cysteine residue binding was performed by comparing the inhibition observed with compounds 5 and 12 using the conditions described for the initial compound screen, in the presence and absence of DTT (5 mM).
Dose Response Relative IC50 values were measured using the reaction conditions outlined
for the initial compound screen, the inhibitory nature of promising compounds was assessed over a range of concentrations (250 μM to 10 nM). Statistical analysis was performed with using GraphPad Prism.
To validate in-house ABAD assay, an IC50 curve was generated for compound AG18051 (the Kissinger inhibitor), a known potent inhibitor of the ABAD enzyme. An IC50 value of 69 nM was generated for compound AG18051 (Fig. 2 ), comparable to the 92 nM reported previously by Kissinger et al., using a cell based system [25] , thus providing evidence that our screening assay is robust in nature. 
QSAR analyses and Pharmacophore modelling 7
The relationship between the structures of the studied compound 1-15 and their inhibition potency towards ABAD/178-HSD10 was analysed by a systematic QSAR analysis. All compounds were prepared for QSAR analyses in HyperChem 8.0 [26] by running a 10 ps long molecular dynamic simulation at constant temperature 310.15K (step 1 fs, bath relaxation time 0.1 ps) using a semiempirical method PM3. After the molecular dynamic simulation phase, the structures were geometrically optimized by Polak-Ribiére conjugate algorithm employing the same PM3 method with the convergence criterion set to 0.03 kcal/(Å.mol). The optimized structures along with the calculated Mulliken charges were imported into Dragon 6 program to generate 4885 various molecular descriptors (e.g. constitutional indices, topological indices, information indices, 2D matrix based descriptors, geometrical descriptors, 3D-MoRSE descriptors, WHIM descriptors, GETAWAY descriptors, drug-like properties, etc.) [27] . The matrix of molecular descriptors and the relative ABAD/17β-HSD10 inhibitions caused by 25 mM were processed in a self-developed C++ based program Statoo using multiple linear regression (MLR) and an exhaustive combinatorial variable selection algorithm evaluating every k-set of molecular descriptors [28] . With the respect to recommended ratio of 1 predictor to 5 or more compounds, we investigated all possible MLR QSAR models containing at most 3 molecular descriptors [29] . The final MLR QSAR top-scoring model was evaluated by leave-one-out, leave-30%-out cross-validation, and also by randomization and scrambling the vector of biological activities [30] . The domain of applicability of the best MLR QSAR model was checked by Williams plot in Matlab 2015.
In order to reveal the most significant structural features of the studied compound for the observed biological activity (i.e. at concentration 25 mM), a pharmacophore analysis was performed.
Initially, the models of 1-15 were prepared by quenched molecular dynamics (QMD) in Open3DAlign program [31] , which uses Tinker to perform molecular mechanics calculations with MMFF94 force field. The QMD protocol was set to carry out a 10 ps simulation at 1000K in vacuum (step size 0.1 fs) and to minimize the geometry till the gradient achieved 0.001 kcal/(Å.mol) or the number of iterations exceeded 1000. For each compound in the set, a conformer library was prepared to be screened in 3D alignment process. A hybrid approach mixing Pharao pharmacophore-based [32] and LAMBDA-like [33] algorithms in Open3DAlign program was utilized to find the best superimposition of all the studied structures on compound 12. Within the alignment process, all combinations between 12 conformers and the other compounds' conformers were aligned to find a superimposition exhibiting maximal O3A score [34] . The best molecular superimposition in the sense of the highest O3A score was investigated by a pharmacophore analysis in LigandScout 3.1 program to derive the substructure influencing most significantly the biological activity. The pharmacophore hypothesis was derived using the most active compounds as a training set.
Cell viability assessment
The effect of compounds on the cell viability was examined using methodology combining LDH and MTT assay into one experimental setup. Such an assay has been chosen due to the fact that widely used MTT test is partially dependent on the mitochondrial oxidoreductases [35] , whose activity might be influenced by the tested compounds targeted to mitochondria. The protocol for this assay has been described previously [36] . Briefly CHO cell line (Chinese hamster ovary, CHO-K1WT2, CRL-1984 ECACC, Salisbury, UK) were cultured according to ECACC recommended conditions and seeded in a density of 8 000 cells per well as was described earlier [37] . Tested compounds were dissolved in DMSO and subsequently in the growth medium (F-12)
supplemented with 1% PEN/STREP without FBS so that the final concentration of DMSO did not exceed 0.5% (v/v). Cells were exposed to a tested compound in the medium (100 µL) for 24 hours. Final IC50 and SEM value was obtained as a mean of at least 3 independent measurements (in triplicate).
EXPERIMENTAL
Chemical preparation
2-aminobenzo[d]thiazole-6-carboxylate
Ethyl 4-aminobenzoate (1 eq.) and KSCN (4 eq.) were dissolved in acetic acid (4 mL/mmol) and stirred at rt for 20 mins. Then the reaction mixture was cooled to 10 °C and bromine (2 eq.) dissolved in small amount of acetic acid was added dropwise. Afterwards the reaction mixture was left to warm up to rt and stirred overnight. After the reaction was completed (monitored by TLC), reaction mixture was added dropwise into the sat. aq. NH3 solution (15 mL/mmol) while cooling in an ice bath. The product was extracted to EtOAc and the organic layer was washed with Na2S2O3, sat. aq. NaHCO3 and brine, dried using anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was either recrystallized from diethylether to obtain ethyl 2- 
General procedure for synthesis of 1-(benzo[d]thiazol-2-yl)-3-phenylguanidines
The corresponding thiourea derivative (1 eq.) was dissolved in 7N methanolic ammonia solution (12 mL/mmol), mercury oxide (3 eq.) was added and the reaction mixture was stirred at room temperature overnight. After the reaction was completed (monitored by TLC), the reaction mixture was filtered over Celite and washed with either THF or MeOH (40 mL/mmol). Evaporation of the filtrate gave corresponding guanidine in poor to good yield (10-79 %). In cases, where further purification was required, the procedure is described together with the respective compound's characterization.
Preparation of hydrochloride salt from guanidine base 12
The guanidine 12 was dissolved in THF, purged with diethylether saturated with gaseous hydrochloric acid and stirred for 1 h at 0 °C. The resulting precipitate was collected by filtration and washed with diethyl ether to obtain guanidine hydrochloride as white solid (90%). 
Prepared compounds and their characterization
RESULTS AND DISCUSSION
Design of novel compounds originates from the previously identified ABAD/ 17β-HSD10 modulator frentizole and its analogues [13] [14] [15] .Our novel compounds consist of three substructural parts i.e. a benzothiazole moiety [38] , a linker and a phenyl moiety (Fig. 3) . The ability of the synthesised compounds to modulate ABAD/17β-HSD10 activity was assessed by a spectrophotometric assay that was formerly outlined by Hroch et al. [24] . An initial compound screen was performed using each compound at 100 μM concentration. All tested compounds, except of the standard frentizole, were found to be capable to markedly decrease the activity of the ABAD enzyme, with nine compounds (2, 4, 5, 8, 9, 11-14) decreasing the activity by more than 50%.A subsequent compound screen was performed at 25 μM in an attempt to isolate the most potent inhibitors. At this lower concentration, compounds 2, 5, 9 and 12 were found to retain a similar level of inhibition as that seen at 100 μM, whilst the remaining inhibitors showed less marked inhibition ( Table 1) . Establishing of the SAR for the presented set of compounds was, however, a difficult task, as there were no clear correlations between the structure of compounds and their inhibitory activity.
There was only one observed trend when the thiourea linked compounds (e.g. 2 and 5) showed mostly higher potency compared to the analogous ureas and guanidines. Nevertheless, the best inhibition was found for the guanidine 12. Different substitutions of the benzothiazole and/or phenyl moieties of the parent frentizole had their effects on the compounds' activity, but without any obvious logical order. To further assess the potency of the two most active inhibitors, compounds 5 and 12, ABAD/ 17β-HSD10 activity was measured in the presence of increasing concentrations of the two inhibitors 16 and their IC50 values calculated using GraphPad Prism. Relative IC50 value of 3.06 ± 0.40 μM was found for compound 12 (Fig. 4 ). The cytotoxicity of the two most potent inhibitors 5 and 12 was assessed using LDH and MTT assay. Cytotoxicity assessment revealed that compound 12 is one order of magnitude less toxic when compared to 5 using two different assays and that its toxicity is at similar level and comparable to parent frentizole (Table 2 ). Both IC50 values obtained for 5 were found similar and it plausibly suggests that the compound 5does not affect the electron transport chain (ETC) of mitochondria (i.e. compound 5 does not inhibit enzymes of ETC) [35] . Differently in the case of compound 12, the IC50 value obtained via a MTT assay was found lower than the LDH assay result, which could be hypothesized to its influence of ETC. However, only small differences between both assays were found that plausibly means only minor influence of mitochondrial ETC and should be further explored for this kind of molecules. The physical-chemical properties were calculated (ACDLabs PhysChem Suite 2014 [20] ) and/or experimentally measured [41] for the two most potent compounds 5 and 12 and the parent compound frentizole ( Table 3 ). The obtained data were compared with optimal properties for CNS targeted drugs [42] [43] [44] . All compounds complied with the optimal values for molecular weight, H-bond acceptors/donors, number of rotatable bonds and ClogP/ElogP values. CLogD7.4/ELogD7.4 values slightly diverged from the optimal range in case of 5 and 12 and all three compounds showed higher than optimal values of total polar surface area (tPSA). Regarding solubility, then only compound 5 did not fit the optimal range for the calculated logS7.4. Generally, a good correlation between the experimental and calculated logP and logD7.4 values was found. Taken together, the compounds 5 and 12 were predicted to penetrate the blood-brain barrier and thus might act within the CNS. However, for future structural design, it will be advantageous to improve some of the physical-chemical properties, especially the tPSA. The domain of applicability of the best QSAR model was demonstrated by William's plot, which displays possible outliers in a conjugate chemical space of the biological activities and the selected molecular descriptors (Fig. 7) . Only compound 12, which exhibited the strongest inhibition activity for ABAD/ 17β-HSD10, is relatively distant from the main cluster of compounds. In general, the QSAR model is well representative for the solved problem. confirms suitability of the model definition.
The above-mentioned statistical validations clearly showed that the developed MLR QSAR model is significant, robust and applicable for ABAD/17β-HSD10 inhibition predictions. The model is built only of three variables: Mv -mean atomic van der Waals volume scaled on carbon atom, JGI6 -mean topological charge index of order 6, and Vs -V total size index weighted by I-state, which enables relatively simple interpretation. If Mv is higher, the observed inhibition potency for ABAD/17β-HSD10 is stronger. This feature may be implied if the carbonyl group is replaced by thiocarbonyl or imino functions. JGI6 descriptor expresses the total charge transfer between atoms at topological distance of 6, and, thus, it is closely related with substitutions at peripheral molecular sites and molecular polarity. The higher the charge transfer (i.e. JGI6), the stronger inhibition of ABAD/17β-HSD10 is elicited. JGI6 descriptor achieves maximal values for compounds 7-12, which are substituted with two 4-methoxy or one 4-ethyl carboxylate functions. On the other hand, Vs molecular descriptor, which belongs to WHIM group, should be less in order to support the inhibition activity. As Vs reflect the spatial molecular extent, a smaller molecules may induce a stronger inhibition. Nonetheless, Mv and Vs have opposite meaning which suggests that a certain optimum of atomic and total molecular size needs to be found.
Pharmacophore analysis of the studied compounds 1-15 in LigandScout 3.1 provided another insight into the relationships between the structure and activity of ABAD/17β-HSD10
inhibitors. By training on the most active substances, a pharmacophore hypothesis was derived and all the compounds were scored according to their fit to it. In Fig. 8 ., an alignment of compounds 5 and 12 with the proposed pharmacophore is demonstrated. Since the set of studied compounds exhibit a high degree of structural similarity, discrimination of inactive structural cores could not fully manifest in the calculations. The present pharmacophore analysis indicated practically the whole structure of compounds 5 or 12 as a pharmacophore. Discriminative power of the pharmacophore model was achieved mainly due to defining exclusion volumes, which enabled differentiation of the most active compounds (e.g. 5, 12, 9) from the least active ones (e. g. 15, 1) . Unfortunately, a robust pharmacophore-based QSAR model giving correct classification all the tested compounds 1-15 according to their inhibition potency was not achieved by this methodology. 
